Sonlicromanol for chronic fatigue in primary mitochondrial disease
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a new medicine, sonlicromanol, to see if it can ease chronic fatigue and improve muscle function in people with a specific genetic condition called primary mitochondrial disease. If effective, it could offer a new treatment option to improve daily energy and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed mitochondrial disease with a specific genetic change (m.3243A>G) and at least 20% of that change in your blood, urine, cheek cells, or muscle.
- You have had fatigue for at least 3 months, and a fatigue score above a certain level at the screening visit.
- You can stand up and sit down from a chair five times in under 30 seconds at the start of the trial.
- You have no serious heart, lung, or digestive problems, and no recent heart procedures or heart rhythm issues that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a special MRI approach (using a contrast agent) to better measure changes in muscles in people with mitochondrial diseases. It also includes some healthy volunteers and other critically ill patients to compare results and check safety.
This Phase 2 trial tests a treatment made from deoxynucleosides to help people with mitochondrial depletion disorder caused by certain gene changes. If you match the genetic diagnosis, the study may see whether the treatment improves symptoms or disease markers.
This trial checks if looking at RNA from blood or skin cells can help diagnose suspected mitochondrial disease. It may help people who have a genetic variant of uncertain significance thought to affect mitochondria.
This is a follow-up study for patients who completed a previous trial (FALCON) testing KL1333, an experimental medicine for primary mitochondrial disease—a condition where cells don't produce enough energy. The study tracks how safe and effective the treatment remains over time.
This trial tests a new treatment for ME/CFS (chronic fatigue syndrome) that includes symptoms like dizziness when standing. It uses a smartphone app to track your progress and aims to see if the treatment can improve your daily life.
This Phase 2 trial studies whether KL1333 improves chronic fatigue and muscle weakness in adults with a confirmed mitochondrial genetic disease. You may be eligible if you have persistent fatigue for at least 3 months and signs of muscle involvement, and can safely follow study requirements.
Hear when a new Mitochondrial Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.